Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Rosen Law Firm PAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC between February 5, 2020 and August 14, 2022. GSK is ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

However, the result has cemented GSK's view that dostarlimab can become the "backbone" of its immuno-oncology R&D programmes, according to the company's head of oncology development, Hesham Abdullah.

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com .

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Law Offices of Howard G. Smith reminds investors of the upcoming April 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased GSK plc. ("GSK" or the ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...